Drug Trial Radar · NCT07332455
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Mar 24, 2028
Study completion Mar 26, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Conditions
- Neoplasms, Prostate
Interventions
GSK5471713Drug
GSK5471713 will be administered at different dose levels based on the dose escalation study design
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs)Time frame: 28 days
- Number of participants with adverse events (AEs), and serious adverse events (SAEs)Time frame: Approximately 45 months
- Number of participants with adverse events (AEs), and serious adverse events (SAEs) by SeverityTime frame: Approximately 45 months
- Number of participants with AEs leading to dose modificationsTime frame: Approximately 45 months
Locations
20 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
La Jolla, California · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
Grand Rapids, Michigan · Recruiting
GSK Investigational Site
Philadelphia, Pennsylvania · Recruiting
GSK Investigational Site
West Valley City, Utah · Recruiting
GSK Investigational Site
Melbourne, Victoria, Australia · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Montpellier, France · Recruiting
GSK Investigational Site
Villejuif, France · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Amsterdam, Netherlands · Recruiting
GSK Investigational Site
Nijmegen, Netherlands · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
GSK Investigational Site
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Málaga, Spain · Recruiting
GSK Investigational Site
Logroño, La Rioja, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.